Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Louis Bourgeois

Showing results (11-20 of 70) with videos related to

Pageof 7
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 6, 2006
Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challengeDavid N Taylor, Robin McKenzie, Anna Durbin, et al.
Frontiers in Immunology|May 6, 2026
The case for evaluation of double mutant heat-labile toxin as an adjuvant to improve oral cholera vaccine immunogenicityA Louis Bourgeois, Daniel A Scott, Shahida Baqar, et al.
Clinical Microbiology Reviews|July 21, 2022
Controlled Human Infection Models To Accelerate Vaccine DevelopmentRobert K M Choy, A Louis Bourgeois, Christian F Ockenhouse, et al.
Vaccine|February 23, 2007
Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge studyRobin McKenzie, A Louis Bourgeois, Sarah A Frech, et al.
Infection and Immunity|January 31, 2007
Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneumGregory M Glenn, Christina P Villar, David C Flyer, et al.
Clinical and Vaccine Immunology : CVI|October 14, 2011
A combination vaccine consisting of three live attenuated enterotoxigenic Escherichia coli strains expressing a range of colonization factors and heat-labile toxin subunit B is well tolerated and immunogenic in a placebo-controlled double-blind phase I trial in healthy adultsClayton Harro, David Sack, A Louis Bourgeois, et al.
Research Square|May 18, 2026
Influence of Gut Microbiota on Immune Responses and Protection in Volunteers Receiving the Live Attenuated Oral ETEC Vaccine ACE257 followed by Virulent ETEC H10407 ChallengeEthan Gough, Soumya Basu, Jessica Brubaker, et al.
The American Journal of Tropical Medicine and Hygiene|June 9, 2006
A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrheaDavid N Taylor, A Louis Bourgeois, Charles D Ericsson, et al.
Clinical and Vaccine Immunology : CVI|November 20, 2015
Characterization of Mucosal Immune Responses to Enterotoxigenic Escherichia coli Vaccine Antigens in a Human Challenge Model: Response Profiles after Primary Infection and Homologous Rechallenge with Strain H10407Subhra Chakraborty, Clayton Harro, Barbara DeNearing, et al.
Journal of Travel Medicine|December 19, 2008
Enterotoxigenic Escherichia coli and diffusely adherent E. coli as likely causes of a proportion of pathogen-negative travelers' diarrhea--a PCR-based studyIsmail M Meraz, Zhi-Dong Jiang, Charles D Ericsson, et al.
Pageof 7

Showing results (11-20 of 70) with videos related to

Sort By:
Pageof 7
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 6, 2006
Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challengeDavid N Taylor, Robin McKenzie, Anna Durbin, et al.
Frontiers in Immunology|May 6, 2026
The case for evaluation of double mutant heat-labile toxin as an adjuvant to improve oral cholera vaccine immunogenicityA Louis Bourgeois, Daniel A Scott, Shahida Baqar, et al.
Clinical Microbiology Reviews|July 21, 2022
Controlled Human Infection Models To Accelerate Vaccine DevelopmentRobert K M Choy, A Louis Bourgeois, Christian F Ockenhouse, et al.
Vaccine|February 23, 2007
Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge studyRobin McKenzie, A Louis Bourgeois, Sarah A Frech, et al.
Infection and Immunity|January 31, 2007
Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneumGregory M Glenn, Christina P Villar, David C Flyer, et al.
Clinical and Vaccine Immunology : CVI|October 14, 2011
A combination vaccine consisting of three live attenuated enterotoxigenic Escherichia coli strains expressing a range of colonization factors and heat-labile toxin subunit B is well tolerated and immunogenic in a placebo-controlled double-blind phase I trial in healthy adultsClayton Harro, David Sack, A Louis Bourgeois, et al.
Research Square|May 18, 2026
Influence of Gut Microbiota on Immune Responses and Protection in Volunteers Receiving the Live Attenuated Oral ETEC Vaccine ACE257 followed by Virulent ETEC H10407 ChallengeEthan Gough, Soumya Basu, Jessica Brubaker, et al.
The American Journal of Tropical Medicine and Hygiene|June 9, 2006
A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrheaDavid N Taylor, A Louis Bourgeois, Charles D Ericsson, et al.
Clinical and Vaccine Immunology : CVI|November 20, 2015
Characterization of Mucosal Immune Responses to Enterotoxigenic Escherichia coli Vaccine Antigens in a Human Challenge Model: Response Profiles after Primary Infection and Homologous Rechallenge with Strain H10407Subhra Chakraborty, Clayton Harro, Barbara DeNearing, et al.
Journal of Travel Medicine|December 19, 2008
Enterotoxigenic Escherichia coli and diffusely adherent E. coli as likely causes of a proportion of pathogen-negative travelers' diarrhea--a PCR-based studyIsmail M Meraz, Zhi-Dong Jiang, Charles D Ericsson, et al.
Pageof 7